Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers

Journal of Clinical Investigation

Volumn 126, Issue 6, 2016, Pages 2181-2190

  Lock, Rebecca ^a,b   Ingraham, Rachel ^a,b   Maertens, Ophélia ^a,b   Miller, Abigail L ^a,b   Weledji, Nelly ^a,b   Legius, Eric ^c,d   Konicek, Bruce M ^e   Yan, Sau Chi B ^e   Graff, Jeremy R ^f   Cichowski, Karen ^a,b,g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e ELI LILLY AND COMPANY   (United States)

^f Biothera   (United States)

^g DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAPK INTERACTING KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NEUROFIBROMIN; UNCLASSIFIED DRUG; ANILIDE; EIF4ENIF1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MULTIPROTEIN COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; THERAPY EFFECT; TUMOR MODEL; TUMOR REGRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MUTATION; NERVE SHEATH NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANILIDES; ANIMALS; CELL LINE, TUMOR; GENES, NEUROFIBROMATOSIS 1; HUMANS; MAP KINASE KINASE KINASES; MICE; MULTIPROTEIN COMPLEXES; MUTATION; NERVE SHEATH NEOPLASMS; NEUROFIBROMIN 1; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84974625192     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85183     Document Type: Article

References (27)

1. Maertens O, Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. Adv Biol Regul. 2014;55:1-14.
2. Martin GA, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990;63(4):843-849.
3. Ballester R, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990;63(4):851-859.
4. Bollag G, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12(2):144-148.
5. Johannessen CM, et al. TORC1 is essential for NF1-associated malignancies. Curr Biol. 2008;18(1):56-62.
6. Chang T, et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J Clin Invest. 2013;123(1):335-339.
7. Jessen WJ, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123(1):340-347.
8. Riccardi VM. Neurofibromatosis: Phenotype, Natural History, And Pathogenesis. Baltimore, Maryland, USA: The Johns Hopkins University Press; 1992.
9. Zehou O, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013;8:127.
10. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005;102(24):8573-8578.
11. Malone CF, Fromm JA, Maertens O, DeRaedt T, Ingraham R, Cichowski K. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov. 2014;4(9):1062-1073.
12. Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75(2):250-263.
13. Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases). Front Biosci. 2008;13:5359-5373.
14. Truitt ML, et al. Differential requirements for eIF4E dose in normal development and cancer. Cell. 2015;162(1):59-71.
15. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24(15):6539-6549.
16. Furic L, et al. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A. 2010;107(32):14134-14139.
17. Ueda T, et al. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci U S A. 2010;107(32):13984-13990.
18. Wendel HG, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007; 21(24):3232-3237.
19. Knauf U, Tschopp C, Gram H. Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2. Mol Cell Biol. 2001;21(16):5500-5511.
20. Konicek BW, et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 2011;71(5):1849-1857.
21. Yan SB, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013;31(4):833-844.
22. Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298-2308.
23. Zou HY, et al. Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012;11(4):1036-1047.
24. Cichowski K, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286(5447):2172-2176.
25. Awad MM, Shaw AT. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014;12(7):429-439.
26. Fabian MA, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-336.
27. Brown AP, Carlson TC, Loi CM, Graziano MJ. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol. 2007;59(5):671-679.